Photo by National Cancer Institute on www.unsplash.com11 Feb 2021
Building Your Gene Therapy Value Story From Day OneChristopher Rudolf

Determining patient prevalence with rare and ultra-rare diseases has long been a challenge for industry, investors and payers. Accurate prevalence data, along with the ability to locate patients that could benefit from a breakthrough ATMP, will enable companies to present their value story from the start of the R&D journey.